TOP > クイック検索 > 外国特許検索 > CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

外国特許コード F170008955
整理番号 (S2015-1669-N0)
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP066393
国際公開番号 WO 2016208348
国際出願日 平成28年6月2日(2016.6.2)
国際公開日 平成28年12月29日(2016.12.29)
優先権データ
  • 特願2015-128139 (2015.6.25) JP
発明の名称 (英語) CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD
発明の概要(英語) [Problem] To clarify the role of stem cell regulation factors, including Matrin-3, in cancer showing neural differentiation such as small cell cancer in the lung, and to develop a drug or the like which is useful for the treatment of cancer with relying on the role. [Solution] In some types of cancer which show a differentiation ability among various types of cancer which have a cancer stem cell regulation mechanism, both a stem cell-maintaining factor and a stem cell differentiation-accelerating factor are expressed at higher levels compared with normal cells and these factors keep a specific balance therebetween. In undifferentiated types of cancer among the above-mentioned various types of cancer, a stem cell-maintaining factor is expressed at a higher level compared with normal cells and these factors keep a specific balance therebetween. In some types of cancer in which the cancer stem cell regulation mechanism is present, there is a specific balance between these stem cell-regulating factors which is different from that in normal cells. In a cancer therapeutic drug and a cancer treatment method according to the present invention, the balance between the above-menioned stem cell-regulating factors is broken down to inhibit the proliferation ability of cancer.
特許請求の範囲(英語) [claim1]
1. The cancer remedy medicine which features that multiplication of the cancer cell is controlled by failing cancer trunk cellular regulation mechanism in the cancer which shows differentiation potency, and the cancer which possesses not yet differentiation,
[claim2]
2. Failure of cancer trunk cellular regulation mechanism, in the claim 1 which features that it is done by controlling the revelation quantity of trunk cellular regulation factor or phosphorylation trunk cellular regulation factor the cancer remedy medicine of statement
[claim3]
3. Failure of cancer trunk cellular regulation mechanism, in the claim 1 which features that it is done by obstructing the phosphorylation of trunk cellular regulation factor or 2 the cancer remedy medicine of statement
[claim4]
4. The aforementioned trunk cellular regulation factor, from the claim 1 which features that it is the trunk cellular regulation factor which exists nuclear in the cancer cell in 3 the cancer remedy medicine of statement
[claim5]
5. Control of the revelation quantity of the aforementioned trunk cellular regulation factor, in the claim 2 which features that by the medicine which designates the anti- trunk cellular regulation factor antibody as the active ingredient the cancer remedy medicine of statement
[claim6]
6. Control of the revelation quantity of the aforementioned phosphorylation trunk cellular regulation factor, in the claim 2 which features that by the medicine which designates the anti- phosphorylation trunk cellular regulation factor antibody as the active ingredient the cancer remedy medicine of statement
[claim7]
7. Control of the revelation quantity of the aforementioned trunk cellular regulation factor, in the claim 2 which features that by the medicine which designates siRNA for trunk cellular regulation factor as the active ingredient the cancer remedy medicine of statement
[claim8]
8. The description above siRNA, in the claim 7 which features that it is the arrangement which from arrangement number 1 is stated in 6 the cancer remedy medicine of statement
[claim9]
9. The aforementioned trunk cellular regulation factor, either Matrin-3, INI1, hnRNPK, MBD3 or SFRS3 or from the claim 1 which features that it is selected from plural in 8 the cancer remedy medicine of statement
[claim10]
10. The cancer which shows differentiation potency, and the cancer which possesses not yet differentiation, from the claim 1 which features that it is the nervous incretion tumor in 9 the cancer remedy medicine of statement
[claim11]
11. The cancer which shows differentiation potency, and the cancer which possesses not yet differentiation, the lung small cell cancer, the leukemia, the breast cancer, the colon cancer, the stomach cancer, the rectum cancer, the skin cancer, the prostate cancer, the ovarian cancer, the uterus body cancer and the pancreas cancer, either the osteosarcoma or the nervous blastoma cancer the empty from the claim 1 which features that it is selected in 9 the cancer remedy medicine of statement
[claim12]
12. Remedy method of the cancer which features that multiplication of the cancer cell is controlled by failing cancer trunk cellular regulation mechanism in the cancer which shows differentiation potency, and the cancer which possesses not yet differentiation,
[claim13]
13. The kit for external diagnosis of cancer which features that the curative effect of the cancer remedy is estimated by inspecting the revelation of the trunk cellular regulation factor in cancer organizing,
[claim14]
14. The organizational fragment is produced from the biopsy sample which includes the cancer cell which was picked by biopsy, revelation of trunk cellular regulation factor is inspected by doing immunity dyeing of trunk cellular regulation factor, the curative effect estimate method of featuring that the curative effect of the cancer remedy medicine is estimated
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • NIIMORI KANAKO
国際特許分類(IPC)
指定国 (WO2016208348)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close